$LGVN

Longeveron Inc - Class A

$LGVN

Longeveron Inc - Class A

Past 12mo:3mentions1voices

All voices2 calls since Jan 2026show all

Loading price chart…

Recent calls

2 calls

@acinvestorblogJan 29, 2026 · 2:18 PM

$LGVN Longeveron Receives Patent From Japan Patent Office Covering Potency Assay Methods For Assessing Human Mesenchymal Stem Cells

Open on X

@acinvestorblogJan 26, 2026 · 2:18 PM

$LGVN Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire January 26, 2026 - ELPIS II top-line trial results are anticipated in the third quarter of 2026 - Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positive - U.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation - Laromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunities - Even with current standard of care surgeries, only 50% of infants survive to adolescence due to right ventricular failure

Open on X

Frequently asked

Who mentions $LGVN most on Surfaced?

@acinvestorblog (Antonio Costa) mentions $LGVN most — 3 mentions in the past 12 months.

When was $LGVN first mentioned on Surfaced?

The earliest tracked mention of $LGVN in the Surfaced archive was on Jan 7, 2026.

How many voices track $LGVN?

1 FinTwit voice has mentioned $LGVN 3 times in the past 12 months.

What kind of voices mention $LGVN most?

$LGVN is mentioned most by Long Research voices on Surfaced.